Trials / Recruiting
RecruitingNCT06930755
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMS-03305293 | Route of administration: Oral |
| DRUG | Topotecan | Route of administration: Intravenous |
Timeline
- Start date
- 2026-04-30
- Primary completion
- 2027-05-31
- Completion
- 2027-09-26
- First posted
- 2025-04-16
- Last updated
- 2026-03-31
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06930755. Inclusion in this directory is not an endorsement.